News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Express Scripts to add Zepbound to National Preferred Formulary
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
The product will be manufactured at Lupin’s Nagpur facility in India
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Subscribe To Our Newsletter & Stay Updated
